司美格鲁肽对美国肥胖或超重患者一年医疗费用的影响真实世界研究

数据集获取（Figshare）

• 源站标题：Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting
• DOI：10.6084/m9.figshare.30305847.v1
• 发布日期：2025-10-08
• 文件数：4 个
• 文件总体积：297.04 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Effects_of_semaglutide_on_one-year_medical_costs_among_patients_with_obesity_or_overweight_in_US_real_world_setting/30305847

命令行下载

curl -L -o "ierp_a_2570688_sm4594.docx" "https://ndownloader.figshare.com/files/58569387"
curl -L -o "ierp_a_2570688_sm4593.docx" "https://ndownloader.figshare.com/files/58569390"
curl -L -o "ierp_a_2570688_sm4592.docx" "https://ndownloader.figshare.com/files/58569393"
curl -L -o "ierp_a_2570688_sm4591.xlsx" "https://ndownloader.figshare.com/files/58569396"

文件清单

• ierp_a_2570688_sm4594.docx（22.72 KB）
• ierp_a_2570688_sm4593.docx（44.43 KB）
• ierp_a_2570688_sm4592.docx（22.74 KB）
• ierp_a_2570688_sm4591.xlsx（207.15 KB）

文件总体积 297.04 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Patients with obesity or overweight are at increased risk for obesity-related complications (ORCs), including cardiovascular disease. Treatment with once-weekly (OW) semaglutide 2.4 mg has demonstrated clinical efficacy, however its impact on healthcare resource utilization (HCRU) and costs warrants further investigation.
This retrospective real-world study evaluated HCRU and costs (excluding pharmacy) among patients with obesity or overweight and ≥1 ORC in the Komodo Healthcare Map database. Baseline characteristics of patients starting OW semaglutide 2.4 mg treatment were matched to obesity medication (OM) non-users. HCRU and medical costs estimates at 12-month follow-up, both all-cause and ORC-related, were compared between the two cohorts.
Patients treated with semaglutide 2.4 mg vs OM non-users had 37% and 21% lower incidence of all-cause inpatient (IP) and emergency room (ER) visits, respectively, and 45% and 29% lower incidence of ORC-related IP and ER visits, respectively. All-cause and ORC-related total medical costs were lower among patients treated with semaglutide 2.4 mg (11% and 15% lower, respectively), translating to an observed savings of $3,342 and $2,408 at 12 months.
In patients with obesity or overweight, OW semaglutide 2.4 mg treatment was associated with decreased total medical HCRU and costs at 12 months.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.30305847.v1（source: https://tandf.figshare.com/articles/dataset/Effects_of_semaglutide_on_one-year_medical_costs_among_patients_with_obesity_or_overweight_in_US_real_world_setting/30305847）。